ロード中...
A phase II study of S-1 in relapsed small cell lung cancer
S-1 is a new oral fluoropyrimidine derivative designed to enhance anticancer activity and reduce gastrointestinal toxicity. This phase II trial aimed to evaluate S-1 in patients with relapsed small cell lung cancer (SCLC). SCLC patients who had experienced treatment failure with ≥1 prior chemotherap...
保存先:
| 主要な著者: | , , , , , , , , , , |
|---|---|
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
D.A. Spandidos
2013
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3915806/ https://ncbi.nlm.nih.gov/pubmed/24649158 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3892/mco.2013.67 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|